Every 10-Q that Ensysce Biosciences Inc (ENSC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENSC filings page.
Ensysce Biosciences, Inc. reported a larger net loss for the six months ended June 30, 2026 as it continues late-stage development of abuse- and overdose‑resistant opioid therapies. Federal grant revenue was $2.13 million, down from $2.69 million a year earlier, while research and development expenses rose to $5.82 million and general and administrative expenses were $2.45 million.
The company recorded a six‑month net loss of $6.13 million and ended June with cash and cash equivalents of only $0.68 million and a stockholders’ deficit of $1.11 million. Management states there is substantial doubt about Ensysce’s ability to continue as a going concern and estimates existing cash will fund operations only through late third quarter 2026, absent new capital.
To date, operations have been financed through grants and equity-linked transactions, including Series B preferred stock financings and multiple warrant offerings and inducements. After quarter‑end Ensysce agreed to acquire Cy Biopharma, Inc. and secured a concurrent private placement for approximately $21.5 million, with the potential for an additional $38.6 million upon achieving specified clinical milestones.
Ensysce Biosciences’ Q1 2026 results highlight rising losses and tight liquidity. Federal grant revenue was $960,999, down from $1,319,772, while operating expenses increased to $4,523,229, driven mainly by higher research and development spending. Net loss widened to $3,556,415 versus $1,945,573 a year earlier.
Cash and cash equivalents fell sharply to $745,482 from $4,310,354 at year-end, and total assets dropped to $2,167,803. Stockholders’ equity turned into a deficit of $669,012, with an accumulated deficit of $143,276,414. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital, despite recent preferred stock and warrant financings.
Ensysce Biosciences is a clinical-stage biotech focused on TAAP and MPAR technologies; PF614 is in Phase 3 and PF614-MPAR is in Phase 1b. The company reported $2.21 million in cash at June 30, 2025 (from $3.50M), total assets of $5.57 million and total liabilities of $2.51 million. For the six months ended June 30, 2025 the net loss was $3.68 million versus $5.08M a year earlier; federal grant revenue was $2.69 million year-to-date and remaining NIH MPAR grant funding was disclosed as $9.4 million as of June 30, 2025. Management discloses substantial doubt about the company’s ability to continue as a going concern and states current cash is sufficient into the third quarter of 2025. Recent financing actions generated gross proceeds of approximately $2.2M from an April 2025 warrant inducement and approximately $1.1M from a March 2025 registered direct offering, with an additional $1.1M raised from warrant exercises after June 30, 2025. The company carries ~3.42M warrants outstanding and has open purchase commitments of about $8.3M.